PLx Pharma Stock Forecast, Price & News

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

Is PLx Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLx Pharma stock.
View analyst ratings for PLx Pharma or view top-rated stocks.

How has PLx Pharma's stock price been impacted by COVID-19?

PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PLXP stock has increased by 107.1% and is now trading at $9.96.
View which stocks have been most impacted by COVID-19.

Are investors shorting PLx Pharma?

PLx Pharma saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 2,650,000 shares, an increase of 24.4% from the October 14th total of 2,130,000 shares. Based on an average daily trading volume, of 433,200 shares, the days-to-cover ratio is currently 6.1 days.
View PLx Pharma's Short Interest.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, March 11th 2022.
View our earnings forecast for PLx Pharma.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.09. The biotechnology company earned $6.60 million during the quarter, compared to the consensus estimate of $4.10 million. PLx Pharma's revenue for the quarter was up 560.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.40) EPS.
View PLx Pharma's earnings history.

What price target have analysts set for PLXP?

4 brokers have issued 1 year target prices for PLx Pharma's stock. Their forecasts range from $14.00 to $29.00. On average, they anticipate PLx Pharma's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 115.9% from the stock's current price.
View analysts' price targets for PLx Pharma or view top-rated stocks among Wall Street analysts.

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the following people:

• Natasha Giordano, President, Chief Executive Officer & Director
• Rita M. O'Connor, CFO, Head-Manufacturing & Supply Chain
• Thomas L. Long, VP-Manufacturing & Technical Operations
• Steven Valentino, Vice President-Trade Sales
• Joanne Cotignola, Vice President-Marketing

Who are some of PLx Pharma's key competitors?

Some companies that are related to PLx Pharma include DICE Therapeutics (DICE), MacroGenics (MGNX), Vectura Group (VEGPF), Merus (MRUS), Nuvalent (NUVL), Arcturus Therapeutics (ARCT), Design Therapeutics (DSGN), Amphastar Pharmaceuticals (AMPH), CannTrust (CNTTF), Tango Therapeutics (TNGX), Edgewise Therapeutics (EWTX), Rani Therapeutics (RANI), Kiniksa Pharmaceuticals (KNSA), Repare Therapeutics (RPTX) and BELLUS Health (BLUSF).
View all of PLXP's competitors.

What other stocks do shareholders of PLx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX).

When did PLx Pharma IPO?

(PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Two Sigma Advisers LP (1.41%), EAM Investors LLC (1.36%), Two Sigma Investments LP (1.19%), BlackRock Inc. (1.04%), Geode Capital Management LLC (0.79%) and First Republic Investment Management Inc. (0.78%). Company insiders that own PLx Pharma stock include John Hadden, Michael J Valentino and Rita M O'connor.
View institutional ownership trends for PLx Pharma.

Which institutional investors are selling PLx Pharma stock?

PLXP stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, and Heritage Way Advisors LLC.
View insider buying and selling activity for PLx Pharma or view top insider-selling stocks.

Which institutional investors are buying PLx Pharma stock?

PLXP stock was bought by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., BlackRock Inc., Two Sigma Investments LP, Morgan Stanley, Two Sigma Advisers LP, EAM Investors LLC, O Brien Greene & Co. Inc, and Bank of New York Mellon Corp. Company insiders that have bought PLx Pharma stock in the last two years include John Hadden, Michael J Valentino, and Rita M O'connor.
View insider buying and selling activity for PLx Pharma or or view top insider-buying stocks.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $9.96.

How much money does PLx Pharma make?

PLx Pharma has a market capitalization of $274.27 million and generates $30 thousand in revenue each year. The biotechnology company earns $-15.21 million in net income (profit) each year or ($3.19) on an earnings per share basis.

How many employees does PLx Pharma have?

PLx Pharma employs 10 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is www.plxpharma.com.

Where are PLx Pharma's headquarters?

PLx Pharma is headquartered at 9 Fishers Lane Suite E, Sparta NJ, 07871.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at (973) 409-6541, via email at [email protected], or via fax at 713-842-3052.